



Respiratory disease in Greece



INTERNATIONAL
RESPIRATORY
COALITION

The International Respiratory Coalition (IRC) was founded to tackle one of global health's most overlooked challenges: the burden of respiratory disease.

We bring together national coalitions of health professionals, patient advocates and policymakers to develop and implement national respiratory health strategies that address prevention, treatment and care.

The ultimate goal is to reduce respiratory disease-related mortality by a third globally by 2030, in line with the UN Sustainable Development Goals.

The Hellenic Respiratory Coalition joined IRC in 2022. Its mission is to develop clear, measurable national strategies to transform respiratory care in Greek society. The coalition's strategic priorities are:

- Prevention through vaccination, preventative care and addressing climate and environmental impacts
- Reducing inequalities by addressing social determinants and prioritising marginalised communities
- Improving access to timely diagnosis and evidence-based treatment across all levels of care
- Advancing research and innovation through AI, real-world data and novel therapies

Societal economic cost by disease:


Asthma
€558.4 million


COPD
€2.2 billion


Lung cancer
€3.8 billion

21.9
thousand
deaths from
respiratory
diseases

1.7
million
people living with
respiratory
diseases

433
thousand
healthy life years
lost to respiratory
diseases


Lower respiratory
tract infections
€1.8 billion


Mesothelioma
€31.2 million


Tuberculosis
€36.2 million


Interstitial lung
disease
€204.5 million


COVID-19
€680.7 million


Pulmonary arterial
hypertension
€35.7 million

€9.4
billion
societal
economic cost
of respiratory
diseases

The IRC is made possible with the contributions of various stakeholders: IRC leadership is provided by the European Respiratory Society and European Lung Foundation; Additional stakeholders include: the IRC National Coalitions and the Global Allergy and Airways Patient Platform; Funding support is provided by AstraZeneca, Chiesi Group, GSK, MSD, Sanofi and Regeneron.

Data taken from IRC Lung Facts <https://international-respiratory-coalition.org/lung-facts/>

Published:
September 2026